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Glucocorticoids (GCs) are widely used to treat acute graft-versus-host disease (aGvHD) due
to their immunosuppressive activity, but they also reduce the beneficial graft-versus-
leukemia (GvL) effect of the allogeneic T cells contained in the graft. Here, we tested
whether aGvHD therapy could be improved by delivering GCs with the help of inorganic–
organic hybrid nanoparticles (IOH-NPs) that preferentially target myeloid cells. IOH-NPs
containing the GC betamethasone (BMP-NPs) efficiently reduced morbidity, mortality, and
tissue damage in a totally MHC mismatched mouse model of aGvHD. Therapeutic activity
was lost in mice lacking the GC receptor (GR) in myeloid cells, confirming the cell type
specificity of our approach. BMP-NPs had no relevant systemic activity but suppressed
cytokine and chemokine gene expression locally in the small intestine, which presum-
ably explains their mode of action. Most importantly, BMP-NPs delayed the development
of an adoptively transferred B cell lymphoma better than the free drug, although the over-
all incidence was unaffected. Our findings thus suggest that employing IOH-NPs could
diminish the risk of relapse associated with GC therapy of aGvHD patients while still
allowing to efficiently ameliorate the disease.
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 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
Glucocorticoids (GCs) are recommended for the initial treatment
of acute graft-versus-host disease (aGvHD), since they potently
suppress the underlying immune response by regulating the
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activity of T cells, macrophages and other cell types [1,2]. How-
ever, their broad range of target cells also entails many side-
effects, including off-target effects such as the induction of muscle
atrophy, osteoporosis, hypertension, and dysglycemia [2–5].
Moreover, GCs also evoke on-target effects related to their
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immunosuppressive activity, i.e., an increased susceptibility to
infections and an impaired antitumor response after HSC trans-
plantation (HSCT), commonly known as the graft-versus-leukemia
(GvL) effect. Hence, new strategies aimed to reduce adverse
effects of GCs while retaining their beneficial activities are needed
and may improve the tolerability of this widely used therapeutic
regimen.
HSCT is often the last option to treat hematopoietic malignan-
cies that do not respond to other conventional therapies [6,7].
The conditioning regimen applied in patients undergoing HSCT
causes tissue damage and initiates an innate immune response,
while the allogeneic T cells contained in the graft recognize major
and minor histocompatibility complex antigens of the recipient
as foreign and cause an adaptive immune response. Eventually,
macrophages and T cells produce pro-inflammatory cytokines and
mediators that attack target organs such as the small intestine,
liver, and skin, an effect that is responsible for the majority of
clinical symptoms observed in aGvHD patients. Application of syn-
thetic GCs such as prednisolone is the standard first-line therapy
of this disease [2,8]. However, there is a considerable number of
aGvHD patients that do not respond to GCs or become resistant
during treatment, in which case second-line therapies are initiated
such as anti-thymocyte globulin or targeted inhibitors of TNF-α
activity. Importantly, most immunosuppressive therapies includ-
ing GCs compromise the GvL effect of the graft as they suppress
T cell functions that are necessary to eradicate residual malig-
nant cells. Efficient amelioration of aGvHD and the concomitant
prevention of a relapse is therefore difficult to achieve.
Studies performed in GC resistant mouse models revealed
that the deletion of the GC receptor (GR) either in allogeneic
T cells or recipient myeloid cells resulted in a severely aggravated
aGvHD regardless of which of the two cell types was refractory
to the activity of endogenous GCs [9,10]. However, the under-
lying mechanisms were different in both models. GC resistance
of allogeneic T cells resulted in an increased cytotoxicity leading
to massive tissue damage in the small intestine and other tar-
get organs, accompanied by a broadly altered gene expression
profile not only affecting T cells but also macrophages and intesti-
nal epithelial cells [11]. In contrast, GC resistance of recipient
myeloid cells had only little effect on gene expression but rather
caused a severe cytokine release syndrome that endogenous GCs
failed to control. In another study, prednisolone treatment of
aGvHD in a haploidentical mouse model was found to reduce
the expression of various cytokines, chemokines, and adhesion
molecules, an effect that was most prominent in the inflamed
intestine [12]. These findings suggest that GCs exert their ben-
eficial activity via different cell types and mechanisms, and that
addressing only some of them might be sufficient to ameliorate the
disease.
GCs reach all tissues with essentially the same efficacy and then
passively diffuse into cells across the plasma membrane. Encap-
sulation of GCs in nanostructures, however, alters both tissue
distribution and uptake efficacy, and thereby allows a more tar-
geted drug delivery [13]. In addition, nanomaterial preferentially
localizes to inflamed tissues due to their extravasation through
leaky vasculature and subsequent inflammatory cell-mediated
sequestration (ELVIS), which is a favorable mechanism in the
treatment of inflammatory diseases [14,15]. Previous publications
reported that GCs encapsulated in PEGylated liposomes preferen-
tially acted on macrophages and monocytes and improved the
treatment of autoimmune diseases [16,17]. Polymer–drug conju-
gates and polymeric micelles containing GCs were also found to
exert potent anti-inflammatory activity in mice while eliciting less
side effects in bone [18–21]. Another recently introduced option
are inorganic–organic hybrid nanoparticles (IOH-NPs) with the
chemical composition [ZrO]2+[(BMP)0.9(FMN)0.1]2− (designated
BMP-NPs). They are made of betamethasone phosphate (BMP), a
synthetic GC derivative frequently used in the clinic, the fluores-
cent dye flavin mononucleotide (FMN), and the inorganic com-
pound zirconium oxide. IOH-NPs have a hydrodynamic diameter
of 30–40 nm and are stable in suspension [22]. They are efficiently
engulfed by macrophages, to a lesser degree by fibroblasts, epithe-
lial cells, and myoblasts, and hardly at all by T and B cells [23].
The uptake of IOH-NPs proceeds via macropinocytosis, followed
by their trafficking to the lysosomal compartment and the release
of the drug. Magnetic resonance imaging of mice revealed a rapid
dissemination of IOH-NPs to abdominal organs including the small
intestine after intraperitoneal injection, and an efficient uptake of
IOH-NPs by myeloid but not T cells in the lamina propria [23].
In addition, BMP-NPs potently ameliorated EAE, a mouse model
of MS [22], suggesting that the new nanoformulation might also
be suitable for the treatment of aGvHD. Importantly, therapeu-
tic efficacy of BMP-NPs in the EAE model was fully dependent
on the modulation of myeloid cells, whereas the activity of GCs
encapsulated in PEGylated liposomes was less specific [16], sug-
gesting that IOH-NPs might have superior features compared to
other nanoformulations.
Here, we set out to test the activity and mechanism of BMP-
NPs using an aGvHD/GvL mouse model. We found that they effi-
ciently mitigated clinical and histological hallmarks of aGvHD and
delayed the development of an adoptively transferred B cell lym-
phoma better than the free drug. These findings recommend BMP-
NPs as an alternative first-line therapy of aGvHD.
Results
BMP-NPs reduce mortality and morbidity in an aGvHD
mouse model
A totally MHC mismatched aGvHD mouse model was used to
assess the therapeutic efficacy of BMP-NPs. In this model, trans-
plantation of bone marrow (BM) cells and splenic T cells from
C57BL/6 mice into irradiated BALB/c mice causes rapidly aggra-
vating clinical symptoms during the first 6–8 days, followed by
a transient amelioration and a subsequent flare-up of the disease
that eventually results in the death of the animals (Fig. 1A).
All mice receiving only BM cells survived until the end of
the experiment. In contrast, most of the mice transplanted with
BM and T cells and injected with the vehicles (PBS or empty
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Figure 1. Impact of GC treatment on mortality and clinical features of aGvHD. BALB/c mice were irradiated and subsequently transplanted with
BM and purified T cells from C57BL/6 mice. In the case of short-term experiments (C and D), treatment with GCs (BMZ or BMP-NP) or vehicles
(PBS or EP-NP) was performed at days 3, 4, and 5. In the case of long-term experiments (B), mice were additionally treated at days 7, 9, and 12.
Mice receiving only BM cells served as a control. (A) Schematic representation of aGvHD experiments and the therapeutic regimen. (B) Survival
of mice based on the applying ethical criteria was monitored for 50 days. N = 4 (BMonly), N = 8/10 (PBS/BMZ), N = 7/10 (EP/BMP-NP); data were
pooled from two experiments. Statistical analysis was done by Log-rank Mantel–Cox test. (C) Development of clinical scores of mice until day 6. N
= 12 (BMonly), N = 21/22 (PBS/BMZ), N = 23/23 (EP/BMP-NP); data were pooled from five experiments. Statistical analysis refers to day 6. (D) Body
temperature of mice at day 6. N = 6 (BMonly), N = 10/12 (PBS/BMZ), N = 9/12 (EP/BMP-NP); data were pooled from three experiments. Values in
panels (C) and (D) are depicted as the mean ± SEM and were analyzed using a one-way ANOVA followed by a Newman–Keuls Multiple Comparison
test. Levels of significance are *p < 0.05; **p < 0.01; ***p < 0.001; n.s., non-significant. The indicated sample size (N) refers to the total number of
individual mice analyzed in each experimental group.
IOH-NPs without the drug, designated EP-NPs) had to be sacri-
ficed until day 10 for ethical reasons (Fig. 1B). When we treated
mice six times during the first 2 weeks (at days 3, 4, 5, 7, 9, and 12)
with free betamethasone (BMZ) or BMP-NPs, survival was signifi-
cantly prolonged compared to the respective vehicle-treated mice
(Fig. 1B). Although BMP-NPs delayed the attainment of the ethical
abort criteria more efficiently than BMZ, the difference between
both treatment groups was small (Fig. 1B).
To evaluate the impact of GC therapy on the severity of clinical
symptoms in the initial phase of the disease, we treated the mice
at days 3, 4, and 5 and followed aGvHD progression until day 6.
Mice receiving only PBS or EP-NPs after BMT cell transfer showed
increasing signs of diarrhea, abdominal pain, and weight loss and
approached the applying abort criteria at the end of the observa-
tion period (Fig. 1C). Treatment of mice with BMZ or BMP-NPs
after BMT cell transfer significantly reduced clinical symptoms,
although to a similar extent in both cases (Fig. 1C). Control mice
receiving only BM cells showed only mild symptoms caused by
the irradiation regimen. It is worth mentioning that mice of the
two vehicle-treated groups also showed a drop in body tempera-
ture compared to mice receiving only BM cells, an effect that was
prevented by injecting BMZ as well as BMP-NPs (Fig. 1D). We
conclude that both GC formulations ameliorate clinical symptoms
in the early phase of aGvHD with similar efficacy, although the
activity of BMP-NPs appears to be more sustained as indicated by
the slightly prolonged survival of mice from this group (Fig. 1B).
Therapeutic activity of BMP-NPs correlates with tissue
damage in the small intestine
Many of the clinical symptoms observed in aGvHD such as diar-
rhea and abdominal pain can be attributed to the extensive tissue
damage caused by the allogeneic T cell response at target sites
such as the small intestine. Hence, we determined pathological
alterations and immune cell infiltration in the small intestine by
histological staining and immunohistochemistry around the first
peak of the disease at day 6. The histopathological score of mice
treated with PBS or EP-NPs was increased in comparison to control
mice whereas the number of goblet cells was reduced (Figs. 2A
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Figure 2. Histological and immunohistochemical evaluation of the small intestine in the early phase of aGvHD after GC treatment. BALB/c mice
were irradiated and subsequently transplanted with BM and purified T cells from C57BL/6 mice. Treatment with GCs (BMZ or BMP-NP) or vehicles
(PBS or EP-NP) was performed at days 3, 4, and 5; mice receiving only BM cells served as a control. Biopsies of the small intestine were collected
at day 6. (A) Histopathological scores obtained by assessment of H&E stained sections of the small intestine. N = 4 (BMonly), N = 9/10 (PBS/BMZ),
N = 9/12 (EP/BMP-NP). (B) Goblet cell numbers per villus determined in PAS stainings of sections of the small intestine. N = 4 (BMonly), N = 11/11
(PBS/BMZ), N = 8/10 (EP/BMP-NP). (C) Numbers of CD3+ cells per square millimeter as determined by counting of immunoreactive cells in sections
of the small intestine. N = 4 (BMonly), N = 11/11 (PBS/BMZ), N = 9/12 (EP/BMP-NP). (D) Quantification of CD68+ cells by measuring the percentage
of the area covered by immunoreactive cells in sections of the small intestine using ImageJ software. N = 4 (BMonly), N = 8/8 (PBS/BMZ), N = 9/12
(EP/BMP-NP). Data in all panels were pooled from four experiments. All values are depicted as mean ± SEM; statistical analyses were performed
by one-way ANOVA followed by a Newman–Keuls multiple comparison test. Levels of significance are *p < 0.05; **p < 0.01; ***p < 0.001; n.s.,
non-significant. The indicated sample size (N) refers to the total number of individual mice analyzed in each experimental group.
and B, and 3). More specifically, the villi in the small intestine
were severely damaged, which was accompanied by the presence
of apoptotic cells, edema, and signs of inflammation (Fig. 3). BMZ
and BMP-NP treatment ameliorated the symptoms as reflected
by lower histopathological scores and increased goblet cell num-
bers (Fig. 2A and B). However, there was no difference between
both treatment groups. Immunohistochemical stainings were per-
formed to take a closer look at the infiltrating leukocytes (Fig. 3).
The numbers of CD3+ T cells and CD68+ myeloid cells were sig-
nificantly increased in aGvHD mice receiving vehicles compared
to BMonly controls (Fig. 2C and D). BMZ treatment prevented the
infiltration of these immune cells into the small intestine, which is
in line with the improved histopathological scores in this experi-
mental group (Fig. 2A–D). Surprisingly, BMP-NPs neither reduced
the number of T cells nor myeloid cells in the small intestine
despite their previously demonstrated ability to ameliorate tissue
damage and clinical symptoms (Fig. 2A–D). Collectively, our find-
ings indicate that both GC formulations impact the disease course
by preserving the tissue integrity of the small intestine and pre-
sumably other aGvHD target organs. BMZ achieves this at least
in part by interfering with immune cell trafficking while BMP-NPs
must employ a different mechanism.
Unaltered T cell and myeloid cell composition in the
small intestine after BMP-NP therapy
Although our immunohistochemical analysis revealed that BMP-
NP treatment did not impact the number of the two major immune
cell subsets in the small intestine, it was still conceivable that their
composition was altered. Namely, CD4+ and CD8+ T cells fulfill
different functions in the pathogenesis of aGvHD, and myeloid
cells can adopt an inflammatory Ly6Chigh or resident Ly6Clow phe-
notype. To determine whether BMP-NPs alter the subtype com-
position of immune cells in target organs, we isolated the cells
from the lamina propria of the small intestine and analyzed them
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Figure 3. Representative photomicrographs of the small intestine in the early phase of aGvHD after GC treatment. BALB/c mice were irradiated
and subsequently transplanted with BM and purified T cells from C57BL/6 mice. Treatment with GCs (BMZ or BMP-NP) or vehicles (PBS or EP-NP)
was performed at days 3, 4, and 5; mice receiving only BM cells served as a control. The small intestine was collected at day 6 from mice of all
five experimental groups and sections were stained with H&E or by PAS reaction. Additional sections were incubated with antibodies recognizing
either CD3 or CD68 to visualize T cells and myeloid cells, respectively. Representative microphotographs aquired at a 100× (H&E) or 200× (PAS,
CD3, CD68) magnification (from the experiments summarized in Fig. 2) are depicted. Size bars: 200 µm (H&E), and 100 µm (PAS, CD3, CD68).
by flow cytometry. The percentage of CD4+ T cells was reduced
in aGvHD mice treated with PBS or EP-NPs compared to con-
trol mice and the percentage of CD8+ T cells was increased, but
neither treatment with BMZ nor BMP-NPs reversed these alter-
ations (Fig. 4A and B). In addition, the percentage of mono-
cytes/macrophages with an Ly6Chigh inflammatory phenotype was
increased in aGvHD mice treated with PBS or EP-NPs in compar-
ison to control mice and the percentage of myeloid cells with a
Ly6Clow resting phenotype was concomitantly decreased (Fig. 4C
and D). BMZ reversed the observed shift in subtype composition,
either by interfering with the de novo recruitment of inflammatory
monocytes/macrophages to the small intestine or by polarizing
them toward an anti-inflammatory phenotype in situ. Importantly,
the composition of myeloid cells in the small intestine was unaf-
fected by BMP-NPs, indicating that GCs delivered via IOH-NPs act
in a different manner than the free drug (Fig. 4C and D).
Myeloid cells are essential targets of the therapeutic
activity of BMP-NPs
Previous studies indicated that IOH-NPs were preferentially taken
up by myeloid cells such as macrophages, for which reason GRlysM
mice lacking the GR in this cell type were refractory to BMP-NP
therapy in a mouse model of MS [22]. To test whether modulation
of myeloid cells was crucial for the BMP-NPs’ therapeutic efficacy
in aGvHD as well, clinical symptoms and pathological hallmarks
were analyzed in GRflox and GRlysM mice at day 6 after aGvHD
induction. GRflox mice injected with EP-NPs developed severe clin-
ical symptoms and a reduced body temperature, and both fea-
tures were mitigated by BMP-NP treatment (Fig. 5A and B). In
contrast, BMP-NPs did not show any therapeutic activity in GRlysM
mice as reflected by their high clinical score and low body tem-
perature, which were both undistinguishable from mice receiving
C© 2020 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
6 Tina K. Kaiser et al. Eur. J. Immunol. 2020. 00: 1–14
Figure 4. Flow cytometric analysis of cells isolated from the lamina propria of the small intestine in the early phase of aGvHD after GC treatment.
BALB/c mice were irradiated and subsequently transplanted with BM and purified T cells from C57BL/6 mice. Treatment with GCs (BMZ or BMP-NP)
or vehicles (PBS or EP-NP) was performed at days 3, 4, and 5; mice receiving only BM cells served as a control. Lamina propria cells were prepared
from the small intestine at day 6 and analyzed by flow cytometry. (A and B) Percentages of CD4+ and CD8+ cells among CD3+ T cells (gated for live
cells and singlets). N = 3 (BMonly), N = 8/5 (PBS/BMZ), N = 5/6 (EP/BMP-NP); data were pooled from three experiments. (C and D) Percentages of
Ly6Chigh and Ly6Clow cells among CD11b+ Ly6Glow monocytes/macrophages (gated for live cells and singlets). N = 4 (BMonly), N = 7/5 (PBS/BMZ), N =
5/6 (EP/BMP-NP); data were pooled from three experiments. All values are depicted as mean ± SEM; statistical analyses were performed by one-way
ANOVA followed by a Newman–Keuls multiple comparison test. Levels of significance are *p < 0.05; **p < 0.01; ***p < 0.001; n.s., non-significant. The
indicated sample size (N) refers to the total number of individual mice analyzed in each experimental group. The gating strategies are illustrated
in Supporting Information Figs. 1 and 2.
EP-NPs (Fig. 5A and B). A similar observation was made concern-
ing tissue damage in the small intestine. GRflox mice injected with
EP-NPs had a high histopathological score and a low number of
goblet cells, both of which were reversed by BMP-NP treatment
(Fig. 5C and D). In contrast, BMP-NP treatment had no effect
on tissue damage in GRlysM mice, indicating that GCs delivered
with the help of IOH-NPs ameliorate aGvHD by acting on myeloid
cells.
Systemic cytokine levels are unaffected by GC therapy
of aGvHD
GR deficiency in myeloid cells was previously found to aggravate
aGvHD due to the inability of endogenous GCs to counteract sys-
temic cytokine secretion [9]. Thus, it was conceivable that ther-
apeutic GCs also acted by reducing pro-inflammatory cytokine
and chemokine levels in the serum. Induction of aGvHD led to
increased concentrations of TNF-α, IL-6, CCL-2, and IFN-γ in the
circulation at day 6, although to a different degree. Surprisingly,
serum levels were similar regardless of whether the mice were
treated with GCs in either formulation or whether they received
the respective vehicles (Fig. 6). This observation indicates that
therapeutic GCs, in contrast to endogenous hormones, have only
little effect on steady-state systemic cytokine and chemokine levels
despite being able to ameliorate aGvHD.
BMP-NPs repress local gene expression of cytokines
and chemokines in the small intestine
Nanosized drug formulations preferentially localize to inflamed
tissues as a consequence of the ELVIS mechanism [14, 15]. In
addition, it was found that IOH-NPs accumulate in the small intes-
tine after intraperitoneal injection into mice and that they are
predominantly taken up by myeloid cells [22,23]. Hence, it was
conceivable that BMP-NPs locally regulate the function of mono-
cytes and macrophages in aGvHD target organs, although their
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Figure 5. Impact of GC treatment on clinical and histological features of aGvHD in the GRlysM mouse model. GRflox and GRlysM mice on a BALB/c
background were irradiated and then transplanted with BM and purified T cells from C57BL/6 WT mice. Treatment with BMP-NPs or EP-NPs was
performed at days 3, 4, and 5; mice receiving only BM cells served as a control. (A) Clinical scores of mice at day 6. N = 4 (BMonly), N = 7/10 (GRflox;
EP/BMP-NP), N = 10/9 (GRlysM; EP/BMP-NP). (B) Body temperature of mice at day 6. N = 4 (BMonly), N = 7/10 (GRflox; EP/BMP-NP), N = 10/9 (GRlysM;
EP/BMP-NP). (C) Histopathological scores obtained by assessment of H&E stained sections of the small intestine collected at day 6. N = 4 (BMonly),
N = 7/7 (GRflox; EP/BMP-NP), N = 8/9 (GRlysM; EP/BMP-NP). (D) Goblet cell numbers per villus as determined in PAS stainings of sections of the small
intestine collected at day 6. N = 3 (BMonly), N = 7/8 (GRflox; EP/BMP-NP), N = 7/8 (GRlysM; EP/BMP-NP). Data were pooled from three experiments.
Values are depicted as the mean ± SEM and were analyzed using a one-way ANOVA followed by a Newman–Keuls multiple comparison test. Levels
of significance are *p < 0.05; **p < 0.01; ***p < 0.001; n.s., non-significant. The indicated sample size (N) refers to the total number of individual mice
analyzed in each experimental group.
number was unaffected by BMP-NPs. To address this issue, we
isolated RNA from the small intestine at day 6 and analyzed it by
quantitative RT-PCR. Induction of aGvHD caused an elevated gene
expression of Tnfa, Il6, Ccl2, Il10, Il2, and Ifng in mice receiving
vehicles compared to BMonly control mice (Fig. 7). Importantly,
treatment with BMZ or BMP-NPs both reduced the mRNA levels
of all genes, although significance was missed for two of them
(Fig. 7). We conclude that IOH-NPs locally act in aGvHD target
organs, where the encapsulated GCs regulate gene expression in
immune cells after their engulfment.
The GvL activity is improved in mice receiving
BMP-NPs compared to free GCs
The allogeneic T cells contained in the graft are not only
responsible for inducing aGvHD but also help eliminating residual
lymphoma cells. Since the latter activity is compromised by any
type of immunosuppressive therapy including GCs, relapses are a
risk in patients receiving HSCT. Since BMP-NPs selectively act on
myeloid cells while being hardly taken up by T cells [22,23], we
hypothesized that this therapeutic regimen might retain the bene-
ficial GvL effect of the graft. To address this issue, we used a com-
bined aGvHD/GvL mouse model (Fig. 8A). Syngeneic Bcl1 lym-
phoma cells were injected into irradiated BALB/c mice followed
by BMT cell transplantation. Control mice receiving only Bcl1 cells
developed a lymphoma characterized by splenomegaly and a high
percentage of malignant cells in the peripheral blood, on which
basis the mice were sacrificed for ethical reasons between day 22
and 27 (Fig. 8B and C). Additional transplantation of BMT cells
and injection of the vehicles PBS or EP-NPs resulted in the
death of all mice before day 10 due to a severe aGvHD (Fig. 8B).
However, when we treated mice receiving Bcl1 and BMT cells with
either of the two GC formulations BMZ or BMP-NPs, survival was
significantly prolonged compared to all other groups (Fig. 8B).
Furthermore, we observed a slight tendency that mice treated with
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Figure 6. Cytokine serum levels in the early phase of aGvHD after GC treatment. BALB/c mice were irradiated and then transplanted with BM
and purified T cells from C57BL/6 mice. Treatment with GCs (BMZ or BMP-NP) or vehicles (PBS or EP-NP) was performed at days 3, 4, and 5; mice
receiving only BM cells served as a control. Blood samples were collected by cardiac puncture at day 6 and serum levels of (A) TNF-α, (B) IL-6,
(C) CCL2, and (D) IFN-γ were determined by ELISA. N = 3–6 (BMonly), N = 9–11 (PBS), N = 5–13 (BMZ), N = 7–11 (EP-NP), N = 8–14 (BMP-NP); data
were pooled from three experiments. Dots correspond to values obtained in individual mice, horizontal lines indicate the mean value. Data were
analyzed using a one-way ANOVA followed by a Newman–Keuls multiple comparison test; levels of significance are *p < 0.05; ***p < 0.001; n.s.,
non-significant. The indicated sample size (N) refers to the total number of individual mice analyzed in each experimental group.
BMP-NPs survived longer than those ones receiving BMZ, which is
in line with our data obtained in the pure aGvHD model (Fig. 1B).
Altogether, these findings led us to conclude that BMP-NPs also
have therapeutic efficacy in a combined aGvHD/GvL model.
To compare the impact of BMZ and BMP-NPs on GvL activity
more directly, we monitored the abundance of lymphoma cells
in the circulation. Mice receiving only Bcl1 cells showed a rapid
expansion of the lymphoma cells in the blood starting around
day 20. In contrast, Bcl1 cells accumulated much later in mice
additionally receiving BMT cells followed by GC therapy due to
the GvL activity associated with the graft (Fig. 8C). Importantly,
lymphomagenesis in mice treated with BMP-NPs was significantly
delayed compared to mice receiving free BMZ, albeit the overall
incidence was largely similar in both groups (Figs. 8C and 9).
These findings suggest that the GvL activity is improved when
GCs are applied via IOH-NPs, resulting in a retarded development
of a B lymphoma.
Discussion
GCs remain the first-line therapy of choice to treat aGvHD,
although overall response rates are unsatisfactory [2]. Further-
more, there is a variety of adverse effects that can accompany GC
therapy such as myopathy, osteoporosis, diabetes, dysglycemia,
hypertension, and infections. However, among the second-line
therapies that are available for the treatment of aGvHD, there
is also none which has been proven superior to another [8], for
which reason efforts are still being made to improve the efficacy
and tolerability of GCs. One clinical trial investigated whether a
combination of methylprednisolone with daclizumab, a human-
ized monoclonal anti-CD25 antibody, improved therapeutic suc-
cess, but survival of patients treated with both drugs was even
diminished [24]. Noteworthy, deaths were related to both aGvHD
and a relapse of the underlying disease. Daclizumab prevents the
proliferation and differentiation of alloreactive T cells including
those ones recognizing residual malignant cells [25]. Hence, it
presumably compromised the GvL effect, resulting in an enhanced
relapse rate. Since daclizumab also depletes regulatory T cells, the
combination therapy additionally enhanced aGvHD mortality
[26,27]. These findings highlight that new strategies are needed
that prevent aGvHD without addressing T cells. This could be
achieved, for instance, by targeting GCs to myeloid cells with the
help of nanoformulations [13]. PEGylated liposomes, polymer–
drug conjugates, polymeric micelles, and hybrid nanoparti-
cles have been found to suppress clinical symptoms in mouse
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Figure 7. Impact of GCs on gene expression of inflammatory mediators in the small intestine in the early phase of aGvHD. BALB/c mice were
irradiated and then transplanted with BM and purified T cells from C57BL/6 mice. Treatment with GCs (BMZ or BMP-NP) or vehicles (PBS or EP-NP)
was performed at days 3, 4, and 5; mice receiving only BM cells served as a control. RNA was isolated from the small intestine at day 6 and
analyzed by quantitative RT-PCR. Relative mRNA levels of (A) Tnfa, (B) Il6, (C) Ccl2, (D) Il10, (E) Il2, and (F) Ifng were calculated by normalization to
the housekeeping gene Hprt. Gene expression in BMonly mice was arbitrarily set to 1. N = 6 (BMonly), N = 7–8 (PBS), N = 7–11 (BMZ), N = 7–10
(EP-NP), N = 8–12 (BMP-NP); data were pooled from three experiments. Values are depicted as the mean ± SEM and were analyzed using a one-way
ANOVA followed by a Newman–Keuls multiple comparison test. Levels of significance are *p < 0.05; **p < 0.01; ***p < 0.001; n.s., non-significant.
The indicated sample size (N) refers to the total number of individual mice analyzed in each experimental group.
models of MS, lupus erythematosus, and ulcerative colitis
[16,20,21]. Only little experience with using nanoformulations,
however, has been made in the context of aGvHD. Delivery of
cyclosporine A with iron nanoparticles improved the survival
of mice after aGvHD induction to a similar extent as the free
drug [28]. Treatment of aGvHD with a dexamethasone palmitate
emulsion that is preferentially taken up by macrophages reduced
clinical symptoms and led to longer survival times compared
to the application of free dexamethasone [29]. It is notewor-
thy that the latter finding is in line with our own observation
that selectively targeting GCs to macrophages by using IOH-NPs
prolongs survival after aGvHD induction at least as efficiently
as the free drug. Hence, there is good evidence that modu-
lating myeloid cell activity suffices to mitigate aGvHD symp-
toms. Since T cell activity is at least partially retained here,
the GvL effect should be improved as it was the case in our
study.
IOH-NPs are a new type of nanoformulation characterized by
a high drug load, i.e., 74 wt% of BMP per nanoparticle, easy syn-
thesis in water, and good tolerability of all constituents [30,31].
They are preferentially taken up by macrophages, less efficiently
by fibroblasts, epithelial cells, and myoblasts, and almost not by T
and B cells [22,23]. After intraperitoneal injection into mice, IOH-
NPs are disseminated to abdominal organs including the small
C© 2020 The Authors. European Journal of Immunology published by
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Figure 8. Mortality and lymphomagenesis
in a combined aGvHD/GvL mouse model
after GC treatment. BALB/c mice were irra-
diated and adoptively transferred with Bcl1
lymphoma cells. Then mice were trans-
planted with BM and purified T cells from
C57BL/6 mice to induce aGvHD. Treatment
with GCs (BMZ or BMP-NP) or vehicles (PBS
or EP-NP) was performed at days 3, 4, 5, 7, 9,
and 12. One group of mice was only trans-
ferred with Bcl1 cells. (A) Schematic repre-
sentation of the aGvHD/GvL experiment and
the therapeutic regimen. (B) Survival of mice
based on the applying ethical criteria was
monitored for 40 days. N = 15 (Bcl1 only),
N = 10 (PBS), N = 14 (BMZ), N = 4 (EP-NP),
N = 10 (BMP-NP); data were pooled from up
to five experiments. Statistical analysis was
done by Log-rank Mantel–Cox test. (C) Aver-
age percentage of Bcl1 cells in the periph-
eral blood as determined by flow cytomet-
ric analysis of λ light chain surface expres-
sion (only mice that did not decease from
aGvHD symptoms were considered in the
graph). N = 15 (Bcl1 only), N = 7 (BMZ), N
= 6 (BMP-NP); pooled from five experiments.
Statistical analysis was performed by one-
way ANOVA followed by a Newman–Keuls
multiple comparison test. Levels of signifi-
cance are *p < 0.05; **p < 0.01; ***p < 0.001;
n.s., non-significant. The indicated sample
size (N) refers to the total number of indi-
vidual mice analyzed in each experimental
group. The gating strategy used for the anal-
ysis of Bcl1 cells in the blood is illustrated in
Supporting Information Fig. 3.
intestine, where they are particularly engulfed by macrophages
[23]. It can be expected that the targeting of IOH-NPs to aGvHD
target tissues is additionally fostered by the ELVIS mechanism,
which is known to cause an accumulation of nanomaterial in
inflamed tissues [14,15]. IOH-NPs should therefore easily reach
the inflamed small intestine and exert their effects locally. In
fact, this is exactly what we observed in our study. Regardless
of the drug formulation, GCs ameliorated clinical symptoms and
tissue damage, but the mechanism by which this was achieved
was different. Free BMZ reduced immune cell infiltration into the
small intestine and altered the composition of the major myeloid
cell subsets. In particular, the accumulation of inflammatory
macrophages was prevented by free BMZ, which could either
be explained by their reduced trafficking to the small intestine
or a polarization of newly recruited macrophages toward an
anti-inflammatory phenotype in situ. Importantly, BMP-NPs had
no effect on these features, suggesting that their therapeutic
efficacy must rely on a different mechanism. In contrast to the
above-mentioned observations, BMZ and BMP-NPs were largely
undistinguishable in regard to their local inhibitory effects on
cytokine and chemokine gene expression in the small intestine.
Our results therefore indicate that the suppression of myeloid cells
in aGvHD target organs probably suffices to mitigate the disease
without the need of any systemic effects or a direct repression of
T cells. The relevance of this conclusion goes beyond the study
at hand as it strongly entails new efforts to target myeloid cells
in aGvHD instead of T cells as it is the case for most currently
employed therapies.
Successful therapeutic intervention after HSCT should not only
prevent the development of aGvHD but also retain the GvL activity
of the allogeneic T cells contained in the graft, and thus prevent
a relapse of the underlying disease. None of the existing aGvHD
therapies including GCs currently fulfill this requirement well. GCs
repress the migration, adhesion, and cytokine expression of T cells
and induce their apoptosis via the intrinsic pathway [32–34]. All
these effects contribute to the repression of aGvHD, but they also
compromise the cytotoxic activity of the T cells needed to destroy
residual malignant cells. Hence, the beneficial and deleterious
effects of free GCs cannot be separated. This is different for GC
nanoformulations such as IOH-NPs that selectively act on myeloid
C© 2020 The Authors. European Journal of Immunology published by
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Figure 9. Bcl1 lymphoma cell expansion in individual mice in a com-
bined aGvHD/GvL model after GC treatment. BALB/c mice were irradi-
ated and adoptively transferred with Bcl1 lymphoma cells. Then, mice
were also transplanted with BM and purified T cells from C57BL/6 mice
to induce aGvHD. BMZ or BMP-NP treatment was performed at days
3, 4, 5, 7, 9, and 12. One group of mice was only transferred with Bcl1
cells. Data refer to the same experiments as depicted in Fig. 8. The
percentage of Bcl1 cells in the peripheral blood was determined by flow
cytometric analysis of λ light chain surface expression and is separately
depicted for each individual mouse. N = 15 (Bcl1 only), N = 14 (BMZ),
N = 10 (BMP-NP); pooled from five experiments. The dashed line refers
to the percentage with which B cells in mice naturally express the λ
light chain. The indicated sample size (N) refers to the total number of
individual mice analyzed in each experimental group.
cells. According to our data, aGvHD is equally well suppressed by
BMP-NPs and free BMZ while it took longer until lymphoma cells
accumulated in the peripheral blood of mice treated with BMP-
NPs. Although our findings indicate that the use of IOH-NPs for
GC delivery enhances the GvL effect of the graft, the incidence of
lymphomagenesis remained largely unaltered. Furthermore, only
a few mice survived beyond day 35. In this context, it is note-
worthy that GCs were only given for a relatively short period of
time and that the therapeutic effect might be more sustained if
the treatment was extended. In addition, a higher GC dose could
result in longer survival times as we have previously shown in
a mouse EAE model that therapeutic efficacy is dose-dependent
[34]. Irrespective of these caveats, the study at hand provides first
evidence that GCs delivered via IOH-NPs retain their therapeutic
activity in aGvHD while improving the GvL activity of the graft.
Materials and methods
Preparation of inorganic–organic hybrid nanoparticles
[ZrO]2+[(BMP)0.9(FMN)0.1]2− IOH-NPs (designated BMP-NPs)
and as a vehicle control [ZrO]2+[(HPO4)0.9(FMN)0.1]2− IOH-NPs
without the drug (designated EP-NPs) were prepared essentially
as described [30]. Synthesis was achieved by admixing a solution
of ZrOCl2 × 8H2O in H2O to a solution of either Na2(BMP) or
Na2(HPO4) together with sodium riboflavin-5’-mono-phosphate
dihydrate (Na(HFMN) in H2O). Thereafter, nucleated IOH-NPs
were separated by centrifugation. BMP-NPs were redispersed in
H2O at a concentration of 2.4–3.2 mg/mL, which corresponds to
4.2–5.5 mM. Since EP-NPs were produced at the same molarity
as BMP-NPs, their mass concentration was accordingly lower.
Quality control of IOH-NP preparations
To unveil a potential contamination of the nanoparticles by endo-
toxins, mice were daily injected with 100 µL BMP-NPs or PBS
i.p. for 2 wks and TNF-α and IL-6 serum levels were analyzed
by ELISA. The lack of any inflammatory response confirmed that
the nanoparticle preparations were free of endotoxins (Supporting
Information Fig. 4A and B).
Animal experimentation
C57BL/6 and BALB/c WT mice were purchased from Janvier
Labs (St. Berthevin, France), whereas GRflox (Nr3c1tm2GSc) and
GRlysM (Nr3c1tm2GScLyz2tm1(Cre)Ifo) mice on a BALB/c background
[9] were bred in our animal facilities at the University Medical
Center Göttingen. All mice were kept in individually ventilated
cages under specific-pathogen-free conditions, supplied with food
and water ad libitum, and used at an age of 8–12 weeks. All exper-
iments were conducted according to Lower Saxony state regula-
tions for animal experimentation and approved by the responsible
authority (Niedersächsisches Landesamt für Verbraucherschutz und
Lebensmittelsicherheit).
Totally MHC mismatched aGvHD mouse model
Bone marrow (BM) was prepared from the long bones of C57BL/6
mice followed by depleting T cells using the EasySepTM Positive
Selection Mouse CD90.2 Kit II (StemCell Technologies, Grenoble,
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France). Splenic T cells were purified with the help of the
EasySepTM Negative Selection Mouse T Cell Isolation Kit (Stem-
Cell Technologies) after passing the organ through a 40 µm cell
strainer. BALB/c mice of the different genotypes were irradiated
with a dose of 8.5 Gy using an X-Ray source operated at 200 kV,
15 mA and 0.5-mm Cu filtration. On the next day, 1 × 107 BM cells
and 2 × 106 T cells were injected via the tail vein (BMT cell trans-
fer) to induce aGvHD [10]. Mice receiving only BM cells served as a
control. Neomycin (25 µg/mL) was added to the drinking water for
up to 3 wks starting 1 day before irradiation to prevent infections.
Clinical symptoms were monitored based on five parameters: pos-
ture, activity, fur ruffling, diarrhea, and weight loss, and depend-
ing on severity, each parameter was assigned a score between 0
and 2. Mice were sacrificed by CO2 inhalation to collect organs for
analysis, or when they reached the abort criteria. Body temper-
ature was measured using a BIO-TK9882 thermometer equipped
with a BIO-BRET-3 rectal probe (Bioseb, Vitrolles, France).
Combined aGvHD/GvL mouse model
Bcl1 lymphoma cells [35–37] were freshly thawed and injected
into irradiated BALB/c mice at a dose of 3000 cells per mouse via
the tail vein. 4 h later, aGvHD was induced and clinical symptoms
were monitored as described above. Lymphoma development was
determined by assessing the percentage of Bcl1 cells in the blood
by flow cytometry starting at day 15. To this end, a drop of blood
was collected from the tail vein and stained with a monoclonal
antibody detecting the λ light chain of the BCR as outlined below.
Mice were sacrificed when reaching the abort criteria defined for
clinical aGvHD symptoms or once the percentage of Bcl1 cells in
the peripheral blood exceeded 50% of all lymphocytes.
Glucocorticoid therapy of aGvHD
Different treatment protocols were applied depending on the
experimental setup. In short-term experiments, GCs were injected
i.p. at day 3, 4 and 5 and the mice were sacrificed at day 6. In
long-term experiments lasting 40–50 days, the treatment was
done at day 3, 4, 5, 7, 9 and 12. Betamethasone (Celestan
R©
,
Merck, Darmstadt, Germany; designated BMZ) was applied at a
concentration of 10 mg/kg body weight, and a similar volume
of PBS served as a control. BMP-NPs were administered at a
dose corresponding to 10 mg/kg BMZ. In this case, a similar
volume of EP-NPs (empty IOH-NPs without the drug) was injected
as a vehicle control, containing the same amount of zirconyl
([ZrO]2+), and largely the same number of particles as BMP-NPs.
Histology
Biopsies of the small intestine were obtained from the central
part of the jejunum and fixed in 4% PFA (Carl Roth, Karlsruhe,
Germany) for 48 h. Following dehydration and embedding in
paraffin, 2 µm sections were prepared and stained with H&E or
by Periodic acid-Schiff (PAS) reaction following standard pro-
cedures. A Leica Axio Scope A1 microscope (Wetzlar, Germany)
was used to acquire photomicrographs. Evaluation of tissue
damage was done in a blinded manner and based on four criteria
(villous blunting/flattening, number of apoptotic cells, grade of
inflammation, and edema) as described previously [38]. To this
end, 10 fields per section were analyzed at 200× magnification
followed by calculating the total histopathological score. Goblet
cell numbers were determined by evaluating 10 fields per section
at 400× magnification.
Immunohistochemistry
Detection of T cells and myeloid cells was achieved by incubating
2 µm tissue sections with EnVision Flex Target Retrival Solution,
Low pH (Dako Agilent Technologies, Santa Clara, CA) followed by
staining for 30 min at room temperature with primary antibodies
recognizing CD3 (1:2000; Santa Cruz Biotechnology) or CD68
(1:200; Abcam, Cambridge, UK). Sites of immunoreactivity were
visualized by using polymeric secondary antibodies coupled to
HRP (ImmPRESS HRP Polymer Detection Kit; Vector Labora-
tories, Burlingame, CA) and DAB (Dako Agilent Technologies).
Photomicrographs were acquired with a Leica Axio Scope A1
microscope after counterstaining the sections with hematoxylin.
Quantification of CD3+ cells was achieved by counting stained
cells in tissue sections at 200× magnification directly under the
microscope. To enumerate CD68+ cells, 10 pictures per tissue
section were taken at 200× magnification, and the stained area
covered by CD68+ cells was determined with the help of ImageJ
software (https://imagej.nih.gov/ij/).
Isolation of lamina propria cells
The small intestine was flushed with PBS, opened longitudinally,
and incubated on ice in PBS containing 3 mM DTT and 60 mM
EDTA (Carl Roth). Subsequently, the epithelial cell layer was
removed by repeated vigorous shaking as described previously
[39]. The remaining tissue was washed with RPMI medium con-
taining 10% FCS and 1% penicillin/streptomycin (Thermo Fisher
Scientific), cut into small pieces and digested for 30 min at 37°C
by using 100 U/mL collagenase II, 100 U/mL collagenase 1A, and
50 U/mL DNaseII type V (all from Sigma–Aldrich, Taufkirchen,
Germany). Single-cell suspensions were obtained by passing the
digested tissue through a 40 µm cell strainer and used for analysis
by flow cytometry.
Flow cytometry
Cells were resuspended in PBS supplemented with 0.1% BSA and
0.01% NaN3 and stained with monoclonal antibodies conjugated
with different fluorochromes (BioLegend, Uithoorn, the Nether-
lands; clone name in brackets): anti-CD3 (17A2), anti-CD4 (RM4-
5), anti-CD8 (53-6.7), anti-CD11b (M1/70), anti-Ly6G (1A8),
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anti-Ly6C (HK1.4), and anti-Igλ (RML-42). An FcR blockade was
performed by using TruStain fcX (anti-mouse CD16/32; clone: 93)
prior to the antibody staining. To remove erythrocytes from blood
samples, they were treated with OptiLyse B (Beckman Coulter).
Data were acquired with an FACS Canto II flow cytometer (BD Bio-
science, Heidelberg, Germany) and analyzed with FlowJo
R©
soft-
ware (Tree Star, Ashland/OR, USA). Gating strategies used for the
analysis of lymphocytes and myeloid cells in the lamina propria
of the inflamed instestine and Bcl1 lymphoma cells in the blood
are illustrated in Supporting Information Figs. 1–3. The employed
method adheres to the “Guidelines for the use of flow cytometry
and cell sorting in immunological studies” [40].
ELISA and quantitative RT-PCR
Serum was prepared from blood samples obtained by cardiac
puncture. IL-6, TNF-α, IFN-γ, and CCL2 levels were determined by
ELISA using commercially available kits according to the manufac-
turer’s instructions (BioLegend or Affymetrix eBioscience, Frank-
furt, Germany). Total RNA was prepared from tissue samples
with the help of the RNeasy Mini Kit (Qiagen, Hilden, Ger-
many) and reverse transcribed into cDNA using the iScript Kit
(Bio-Rad, Munich, Germany). Quantitative RT-PCR employing the
SYBR green mastermix was performed on an ABI 7500 instrument
(both Applied Biosystems, Darmstadt, Germany). Gene expres-
sion was normalized to the mRNA levels of Hprt and evaluated
using the Ct method. All primers were synthesized by Metabion
(Planegg, Germany); sequences are available upon request.
Statistical analysis
Kaplan–Meier survival curves were analyzed with the Log-rank
Mantel–Cox test; in all other cases, a one-way ANOVA followed
by a Newman–Keuls multiple comparison test was used. A Grubbs’
test was employed to identify outliers in data sets. Statistical
analyses were done with Prism
R©
software (GraphPad Software,
San Diego, CA). Levels of significance: *p < 0.05, **p < 0.01,
***p < 0.001, n.s., non-significant.
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